BioXell Acquires Novel Compound From Roche
12 janv. 2007 01h54 HE
|
BioXell SpA
MILAN, Italy, Jan. 12, 2007 (PRIME NEWSWIRE) -- BioXell S.p.A. (SWX:BXLN) today announced its decision to exercise the option rights it acquired from Roche for BXL746, a novel vitamin D3 analogue....
BioXell Completes Recruitment for Phase IIb Trial of Elocalcitol in Benign Prostatic Hyperplasia
15 déc. 2006 01h42 HE
|
BioXell SpA
MILAN, Italy, Dec. 15, 2006 (PRIME NEWSWIRE) -- BioXell S.p.A. (SWX:BXLN) today announced that it has completed recruitment on schedule for its Phase IIb trial of lead compound Elocalcitol in Benign...
Reminder -- BioXell's R&D Day in Zurich - Friday, October 13
09 oct. 2006 13h30 HE
|
BioXell SpA
ZURICH, Oct. 9, 2006 (PRIMEZONE) -- BioXell (Frankfurt:B4X) announced the following reminder:
"Following the invitation sent on September 27, we wish to remind you that BioXell's R&D Day will...
BioXell: Invitation to R&D Day
27 sept. 2006 02h11 HE
|
BioXell SpA
ADVISORY, Sept. 27, 2006 (PRIMEZONE) -- BioXell is pleased to invite you to its R&D day, whose purpose will be to provide an in-depth overview of the Company's clinical and pre-clinical R&D...
BioXell Plans Phase IIb European Trial for Elocalcitol in Overactive Bladder
28 juil. 2006 02h07 HE
|
BioXell SpA
MILAN, Italy, July 28, 2006 (PRIMEZONE) -- BioXell S.p.A. (SWX:BXLN) today announced its plans to proceed with a Phase IIb clinical trial of its lead compound Elocalcitol in Overactive Bladder (OAB)....
BioXell Enters License Agreement with Merck & Co., Inc. for TREM-1 Product Candidate and TREM Platform
23 mai 2005 07h11 HE
|
BioXell SpA
MILAN, Italy, May 23, 2005 (PRIMEZONE) -- BioXell SpA, the Italian biopharmaceutical company, today announced that it has signed an exclusive, worldwide license agreement with Merck & Co., Inc....
BioXell and ProSkelia Announce R&D Collaboration
12 janv. 2004 04h22 HE
|
BioXell SpA
MILAN, Italy and PARIS, Jan. 12, 2004 (PRIMEZONE) -- BioXell SpA and ProSkelia SAS today announced the signing of a collaborative agreement to research and develop drug candidates based on Vitamin D3...
BioXell's Phase IIa trial in BPH is fully enrolled
28 nov. 2003 04h16 HE
|
BioXell SpA
MILAN, Italy, Nov. 28, 2003 (PRIMEZONE) -- Milan, Italy, November 28, 2003 - BioXell SpA, today announced that it has completed patient enrolment in the Phase IIa trial of its novel lead compound,...
BioXell Expands its Scientific Advisory Board
13 oct. 2003 03h10 HE
|
BioXell SpA
MILAN, Italy, Oct. 13, 2003 (PRIMEZONE) -- BioXell SpA, today announced the appointment of Professor Karl Erik Andersson and Professor Roger Bouillon to the Company's Scientific Advisory Board (SAB)....
BioXell Appoints Director, Business Development & Commercial Strategy
15 sept. 2003 04h22 HE
|
BioXell SpA
MILAN, Sept. 15, 2003 (PRIMEZONE) -- BioXell SpA, today announced the appointment of Meenu Chhabra, BSc, MBA as Director of Business Development and Commercial Strategy with immediate effect.
Ms...